CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to RHHBY

Obinutuzumab/Intravenous

Phase 2
Roche Holding AG (RHHBY)

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Nov '26
RHHBYPDUFA
Phase 2

FDA PDUFA Date Obinutuzumab (Gazyva)

Obinutuzumab/Intravenous
Nov 2026~
Source
00%
Competitive Landscape

2 competitors in Follicular Lymphoma

View Full Landscape
Drug Information

Target Indication

Follicular Lymphoma

Clinical Trial

NCT04962126

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.